aura6000 system
LivaNova USA, Inc. · Decision date Jun 18, 2026
What did the FDA approve?
FDA records P250013/S002 as a supplement to PMA P250013, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jun 18, 2026.
FDA approval order statement
approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250013
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Anesthesiology
- Decision date
- Jun 18, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P250013/S002
- Regulatory pathway
- PMA supplement
- Applicant
- LivaNova USA, Inc.
- Product code
- MNQ
- Decision code
- APPR
- Decision date
- Jun 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, hypoglossal nerve, implanted, apnea.
- Applicant
- LivaNova USA, Inc.
- Product code
- MNQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250013 · Original PMA
aura6000 system
P250013/S001 · Related supplement
aura6000 system
P250013/S002 received
Application receipt date recorded by FDA.
P250013/S002 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P250013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
aura6000 systemP250013 | LivaNova USA, Inc. | PMA approval | Mar 18, 2026 | FDA |
aura6000 systemP250013/S001 | LivaNova USA, Inc. | PMA supplement | Apr 30, 2026 | FDA |
Explore the linked device profile
Other records with product code MNQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Model 4063 Dedicated Tray SealerP130008/S148 | Inspire Medical Systems | PMA supplement | Nov 5, 2026 | FDA |
INSPIRE II UPPER AIRWAY STIMULATORP130008/S144 | Inspire Medical Systems | PMA supplement | Oct 26, 2026 | FDA |
Model 3150 IPGP130008/S147 | Inspire Medical Systems | PMA supplement | Oct 22, 2026 | FDA |
Model 3150 IPGP130008/S146 | Inspire Medical Systems | PMA supplement | Oct 13, 2026 | FDA |
INSPIRE II UPPER AIRWAY STIMULATORP130008/S123 | Inspire Medical Systems | PMA supplement | Aug 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
LivaNova USA, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 100 Cyberonics Blvd., Houston, TX, 77058
Sources and methodology
- Original FDA record: P250013/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




